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Sir,
We read with interest the publication by Hoey et al (2003), on
MCF-7 cell proliferation promoted by the overexpressed PTH/
PTHrP receptor, since a study on the effects of PTHrP on MCF-7
cell proliferation is currently in progress in our Lab.
We knew that the old and new literature reports contradictory
findings in this cancer cell line as far as the proliferative response
is concerned; it is surprising, however, that the question is still
open in 2003. To our knowledge, the first study on PTHrP and
MCF-7 cells is the one by Birch et al (1995), cited in Hoey’s paper.
However, discordant results had already been presented in 1981
(Cho-Chung et al, 1981). Birch’s group found a mitogenic effect of
PTH and PTHrP on MCF-7 cells, with a parallel increase in cAMP
intracellular levels. Therefore, the work by Hoey et al (2003)
appears to support Birch’s findings.
Conversely, more recent studies, also cited in the paper, show
that the cAMP pathway inhibits proliferation in MCF-7 cells (Chen
et al, 1998).
The recent report by Tovar Sepulveda et al (2002), focused on
PTHrP and MCF-7, is particularly instructive here, although it
does not meet the question of the different response to PTHrP
by the same cell. They clearly demonstrated that PTHrP
possesses a double signalling on MCF-7: an antimitogenic pathway
mediated by the membrane receptor and a second wave of
signalling, pro-proliferative and antiapoptotic, based on nuclear
localisation of the peptide. The same dual effect had also
been described in vascular smooth muscle cells in 1997
(Massfelder et al, 1997).
We believe that this controversial aspect is not discussed enough
in Hoey’s article. However, we can realise that in May 2002, the
date of the first submission, the author could not have read the
paper by Tovar Sepulveda et al (2002). On the contrary, Hoey knew
and cited the work by Falzon and Du (2000). He suspects that
Falzon’s results about the intracrine effect of PTHrP in PTHrP-
transfected MCF-7 cells is of poor physiological relevance, since it
is unlikely that the same phenomenon takes place in parental cells
as well.
We agree that transfection, in general, may confer cell
characteristics completely different from those of the parental
one and this is the main risk in transfection experiments. However,
the same remark could be made to Hoey’s results, too.
Our preliminary results, summarised in Figure 1, strongly differ
from Hoey’s ones. In fact, our MCF-7 cells respond to 640nM
PTHrP, in contrast to Hoey’s cells, which are unresponsive to
125nM PTHrP.
This is the first difference with Hoey’s work.
On working with parental MCF-7 cells, we needed to increase the
PTHrP dose to obtain some effect on proliferation. We also failed
to appreciate significant variations below the dose of 640nM. Thus,
MCF-7 cells are not unresponsive to PTHrP; they simply need a
stronger treatment.
Our results (still incomplete to be collected in a manuscript) also
indicate that exogenous PTHrP triggers two main transduction
pathways: the adenylyl-cyclase (AC)/protein kinase (PK) A and the
phospholipase (PL) C/PKC cascade. Thus, the native PTH/PTHrP
receptor is coupled also to the Ca
2þ signalling route in MCF-7
cells.
This is the second difference: Hoey’s cells have probably lost this
transduction pathway.
In our MCF-7 cells, both PKA and PKC are antimitogenic and
this appears to be the main difference. We cannot tell, at the
moment, which is the major player, but the selective block of AC or
PLC reduces the antiproliferative effect of PTHrP.
We chose to block the membrane enzymes, rather than PKs,
because, as reported also by Hoey, chemical inhibitors of PKs are
toxic for cells and mask the proliferative effect of a test factor.
This is the only experience we have in common with Hoey’s
group.
Hoey describes an effect of PTHrP on cell sensitivity to growth
factors, but this is not a novel phenomenon, as it was already
described by Linseman et al (1995). Probably, Hoey is dealing
with the so-called transactivation of growth factors tyrosine kinase
(TK) receptors by PTHrP G-protein-coupled receptor (GPCR)
(Linseman et al, 1995; Lowes et al, 2002). We observed a
similar phenomenon in 2002 while culturing skin fibroblasts in
the presence of serum (then of growth factors) (Maioli et al,
2002).
We do not have the presumption to solve the conflict be-
tween Hoey’s and our results, but in an attempt to reconcile
them, we hypothesise that the overexpressed receptor, unable to
couple to PLC, thus lacking one of the two antiproliferative
pathways, acquired enhanced ability to transactivate TK receptors;
the pro-mitogenic effect predominates in the presence of 2%
serum.
We believe that such a pro-proliferative action of PTHrP,
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PTHrP shares pro-mitogenic properties in 2.5% serum-cultured
MCF-7 cells, when the membrane AC and PLC are simultaneously
blocked.
Finally, the main question and the only one that cannot be
ascribed to the transfection process is the opposite effect of
forskolin (an AC activator) on parental (ours) and transfected
MCF-7 cells (Hoey’s ones). In fact, it is now clear that cAMP can
exert both pro- and antimitogenic effects acting at the level of
different Raf isoforms. As a rule, the cAMP/PKA pathway
stimulates Ras-independent and Rap-1-dependent extracellular
regulated kinase (ERK) phosphorylation and cell proliferation in
Raf-B-expressing cells, but it inhibits growth in Raf-B-negative
cells (Fujita et al, 2002).
Then, is the difference in cAMP levels sufficient to explain the
discrepancy?
Our previous experience on skin fibroblasts, which
express predominantly the Raf-1 isoform (Fortino et al, 2002),
indicates that forskolin (then cAMP) is always antiproliferative,
at any dose tested (Maioli et al, 2002). Consistently, in our
MCF-7 cells, forskolin (as well as phorbol 12-myristyl 13-acetate,
PMA) mimics the PTHrP antimitogenic effect. Although a
study focused on Raf isoforms in MCF-7 cells is still missing,
Raf-1 isoform is surely expressed (Weinstein-Oppenheimer et al,
2001).
Clarifying this and the other aspects would add significantly to
our present biological and clinical knowledge on PTHrP role and
responsibility in cancer.
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Figure 1 Proliferative response of MCF-7 breast cancer cells to 640nM
PTHrp 1–40. Cells were grown in MEM in the presence of 2.5% FCS.
Chemical inhibitors and activators were used at the following doses: SQ
22536: 50mM; Forskolin (FK): 100mM; U 73122: 20mM; PMA: 0.3mM. Results
are expressed as % of the control. Data are the mean value7s.d. of two
independent experiments, each performed in duplicate.*Significantly
different from the control (Po0.05).
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